Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480

doi:10.3748/wjg.v9.i6.1241

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2872)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

411

HTML

2156

Figures (1-5)

305

Sum=2872

Jun 15, 2003 (publication date) through Oct 3, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Colorectal Cancer

World J Gastroenterol. Jun 15, 2003; 9(6): 1241-1245
Published online Jun 15, 2003. doi: 10.3748/wjg.v9.i6.1241

Full Size Figure Download Figure

Figure 1 Effect of TRAIL on SW480 cells. SW480 cells were treated with TRAIL at the concentrations of 0, 10, 100, 500 and 1000 μg•l^-1 for 24 h. Cell growth inhibition was assessed by MTT assay and confirmed by flow cytometry assay. Compared with TRAIL-sensitive leukaemic cell line Jurkat (IC₅₀ 0.42 μg•l^-1), SW480 cells (IC₅₀ > 1000 μg•l^-1) were not responsive to TRAIL at concentration more than 100 times those active on Jurkat.

Citation: Xu LH, Deng CS, Zhu YQ, Liu SQ, Liu DZ. Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480. World J Gastroenterol 2003; 9(6): 1241-1245
URL: https://www.wjgnet.com/1007-9327/full/v9/i6/1241.htm
DOI: https://dx.doi.org/10.3748/wjg.v9.i6.1241